NASDAQ:CTCX Carmell (CTCX) Stock Price, News & Analysis → Will this AI Micro-Cap be Bigger than NVIDIA? (From Behind the Markets) (Ad) Free CTCX Stock Alerts $1.81 -0.02 (-1.09%) (As of 08:35 AM ET) Add Compare Share Share Today's Range$1.81▼$1.8150-Day Range$1.98▼$2.6552-Week Range$1.70▼$13.31Volume250 shsAverage Volume8,593 shsMarket Capitalization$37.65 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Carmell alerts: Email Address Carmell MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy0.27% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.84Based on 5 Articles This WeekInsider TradingAcquiring Shares$58,499 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.23 out of 5 starsMedical Sector900th out of 913 stocksSurgical & Medical Instruments Industry97th out of 98 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Carmell.Read more about Carmell's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.27% of the float of Carmell has been sold short.Short Interest Ratio / Days to CoverCarmell has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Carmell has recently increased by 18.33%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCarmell does not currently pay a dividend.Dividend GrowthCarmell does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CTCX. Previous Next 2.7 News and Social Media Coverage News SentimentCarmell has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Carmell this week, compared to 0 articles on an average week.MarketBeat Follows1 people have added Carmell to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Carmell insiders have bought more of their company's stock than they have sold. Specifically, they have bought $58,499.00 in company stock and sold $0.00 in company stock.Percentage Held by InstitutionsOnly 24.22% of the stock of Carmell is held by institutions.Read more about Carmell's insider trading history. Previous Next 0.0 Earnings and Valuation Price to Book Value per Share RatioCarmell has a P/B Ratio of 1.69. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Carmell's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Prosper Trading Academywhy 99.94% won’t make you moneyI believe there's only 5-7 stocks that you should trade in 2024. But here's the catch…because there's always a catch in life. You NEED to use a specific system when you trade them.Click here to download my options trading cheat sheet (5-7 stocks inside here) About Carmell Stock (NASDAQ:CTCX)Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. In addition, the company is also developing a line of men's products and a line of topical haircare products. It has licensing agreement with Carnegie Mellon University to develop and commercialize biocompatible plasma-based plastics. The company was formerly known as Carmell Therapeutics Corporation and changed its name to Carmell Corporation in November 2023. Carmell Therapeutics Corporation was founded in 2008 and is headquartered in Pittsburgh, Pennsylvania.Read More CTCX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CTCX Stock News HeadlinesMay 23, 2024 | insidertrades.comRajiv Shukla Purchases 8,680 Shares of Carmell Co. (NASDAQ:CTCX) StockJune 18 at 2:06 AM | americanbankingnews.comShort Interest in Carmell Co. (NASDAQ:CTCX) Expands By 18.3%May 25, 2024 | finance.yahoo.comCarmell Corporation (CTCX)May 16, 2024 | investorplace.comCTCX Stock Earnings: Carmell Therapeutics Reported Results for Q4 2023May 16, 2024 | investorplace.comCTCX Stock Earnings: Carmell Therapeutics Reported Results for Q1 2024April 11, 2024 | globenewswire.comCarmell Announces Successful Closing of $3.0 Million Private PlacementApril 4, 2024 | globenewswire.comCarmell Announces $3.0 Million Private PlacementMarch 27, 2024 | globenewswire.comCarmell Announces Successful Closing of Axolotl Biologix Sale TransactionMarch 22, 2024 | investing.comCarmell Corporation divests subsidiary to focus on skincareMarch 20, 2024 | globenewswire.comCarmell Sharpens Aesthetics Focus with Execution of Definitive Agreement to Sell Axolotl Biologix SubsidiaryMarch 18, 2024 | globenewswire.comCarmell to Host Investor Webinar, “Unveiling the Secretome: On the Eve of Product Launch” Featuring Key Opinion Leaders in the Medical Aesthetics FieldFebruary 28, 2024 | morningstar.comCarmell Corp Ordinary Shares - Class AFebruary 26, 2024 | msn.comWhy Freshpet Shares Are Trading Higher By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day SessionFebruary 26, 2024 | globenewswire.comCarmell Announces Product Development Completed for G.L.E.E. Launch in March 2024January 6, 2024 | nasdaq.comCarmell Corporation Common Stock (CTCX)December 9, 2023 | morningstar.comCarmell Corp Ordinary Shares - Class A CTCXNovember 29, 2023 | msn.comCarmell CEO buys shares worth over $15.5k - filingNovember 16, 2023 | finance.yahoo.comCarmell Corp Announces Addition of Scott Frisch and Gilles Spenlehauer to Board of DirectorsSeptember 12, 2023 | finance.yahoo.comMoonshot Client Axolotl Announces Merger with Carmell Therapeutics, Elevating the Field of Regenerative MedicineSeptember 5, 2023 | finance.yahoo.comCarmell Corporation Announces Completion of Post-Merger Integration with Axolotl Biologix and New Organizational Structure Aligned with Focus on AestheticsAugust 19, 2023 | seekingalpha.comCTCX Carmell Therapeutics CorporationAugust 9, 2023 | finance.yahoo.comCarmell Announces Successful Closing of Merger with Axolotl Biologix and Launch of a New Brand IdentityAugust 6, 2023 | ca.finance.yahoo.comCarmell Therapeutics Corporation (CTCX)August 1, 2023 | morningstar.comCarmell Therapeutics Corp Ordinary Shares - Class AJuly 28, 2023 | barrons.comCarmell Therapeutics Corp.See More Headlines Receive CTCX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Carmell and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today6/18/2024Next Earnings (Estimated)8/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:CTCX CUSIPN/A CIK1842939 Webwww.carmellrx.com Phone412-894-8248FaxN/AEmployees9Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-15,440,000.00 Net MarginsN/A Pretax Margin-401.27% Return on Equity-171.27% Return on Assets-22.94% Debt Debt-to-Equity RatioN/A Current Ratio0.75 Quick Ratio0.75 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.07 per share Price / Book1.71Miscellaneous Outstanding Shares20,803,000Free FloatN/AMarket Cap$38.07 million OptionableNot Optionable Beta0.53 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Rajiv Sarman Shukla (Age 49)Executive Chairman & CEO Comp: $292.19kMr. Bryan J. Cassaday (Age 55)Chief Financial Officer Comp: $261.7kDr. Phil Campbell Ph.D.Founder and Chief Scientific OfficerDr. Lee Weiss Ph.D.FounderDr. James Burgess M.D.FounderKey CompetitorsAlpha Tau MedicalNASDAQ:DRTSTriSalus Life SciencesNASDAQ:TLSIClearPoint NeuroNASDAQ:CLPTQuipt Home MedicalNASDAQ:QIPTTELA BioNASDAQ:TELAView All CompetitorsInsiders & InstitutionsRichard A UptonBought 2,000 shares on 6/12/2024Total: $4,400.00 ($2.20/share)Bryan J CassadayBought 440 shares on 6/10/2024Total: $1,100.00 ($2.50/share)Rajiv ShuklaBought 2,100 shares on 6/6/2024Total: $5,523.00 ($2.63/share)Rajiv ShuklaBought 2,000 shares on 5/30/2024Total: $5,000.00 ($2.50/share)Bryan J CassadayBought 30 shares on 5/29/2024Total: $78.00 ($2.60/share)View All Insider TransactionsView All Institutional Transactions CTCX Stock Analysis - Frequently Asked Questions How have CTCX shares performed in 2024? Carmell's stock was trading at $3.81 at the beginning of the year. Since then, CTCX shares have decreased by 52.5% and is now trading at $1.81. View the best growth stocks for 2024 here. Are investors shorting Carmell? Carmell saw a increase in short interest in the month of May. As of May 31st, there was short interest totaling 35,500 shares, an increase of 18.3% from the May 15th total of 30,000 shares. Based on an average daily trading volume, of 10,700 shares, the short-interest ratio is currently 3.3 days. Approximately 0.3% of the shares of the stock are sold short. View Carmell's Short Interest. When is Carmell's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 21st 2024. View our CTCX earnings forecast. How were Carmell's earnings last quarter? Carmell Co. (NASDAQ:CTCX) announced its quarterly earnings data on Wednesday, May, 15th. The company reported ($0.16) EPS for the quarter. Who are Carmell's major shareholders? Carmell's stock is owned by many different retail and institutional investors. Top institutional investors include Hubbell Strickland Wealth Management LLC (0.07%). Insiders that own company stock include Bryan J Cassaday, Gilles Spenlehauer, Rajiv Shukla, Randolph W Hubbell, Richard A Upton and Scott M Frisch. View institutional ownership trends. How do I buy shares of Carmell? Shares of CTCX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CTCX) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredRadical change coming — do this NOW to protect yourselfI recently uncovered a way the government could use the next crisis as a pretext to gain more control … and ra...Weiss Ratings | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredKiss of death from Joe BidenI did not consent. You did not consent. It’s in direct violation of the U.S. Constitution but Biden does ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Carmell Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Carmell With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.